Effect of Adding Hyaluronidase to Bupivacaine in Transversus Abdominis Plane Block for Cesarean Section

Effect of Adding Two Different Doses of Hyaluronidase to Bupivacaine in Ultrasound-Guided Transversus Abdominis Plane (TAP) Block for Post-cesarean Section Analgesia; A Randomized Controlled Double Blinded Study.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05671172

Enrollment

114

Registered

2023-01-04

Start date

2023-05-15

Completion date

2024-02-10

Last updated

2025-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Brief summary

Since TAP block needs to affect several nerves in single tissue plane with a single prick, hyaluronidase is expected to aid greatly in the spread of the LA and help the block. However, there have not been adequate studies to establish the efficacy of adding hyaluronidase in lateral TAP after cesarean section. Hence, the present study was carried out to evaluate the efficacy of hyaluronidase in different concentrations added to bupivacaine in US-guided bilateral lateral TAP block.

Interventions

DRUGHyaluronidase

hyaluronidase will be applied as adjuvant to bupivacaine in transversus abdominis plane block to enhance the postoperative analgesic effect after CS

DRUGBupivacaine Injection

20ml bupivacaine will be injected without additives in the transversus abdominis plane block on each side for postoperative analgesic after CS

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* parturients who aged between 18-40 years old * with ASA physical status grade II and * scheduled for elective CS under spinal anesthesia

Exclusion criteria

* patients with ASA grade III or IV, * refusal to participate, * emergency CS or complicated pregnancy, * those with bleeding disorders or on anticoagulants, * those with severe respiratory and cardiovascular diseases, * having any local infection at the injection site, * history of allergy to one of the used drugs, * obese patients (body mass index ≥ 30 kg/m2).

Design outcomes

Primary

Measure	Time frame	Description
the duration of analgesia	24 hours postoperative	the interval between performing the block and the time of the first request for analgesia.

Secondary

Measure	Time frame	Description
the postoperative pain severity	every 0,2,4,8,12, up to 24 hours postoperative	pain was assessed by the visual analog scale (VAS) pain score (range, 0-10; 0, no pain; 10, worst pain)
total morphine consumption	at 24 hours postoperatively	—
patient satisfaction	at 24 hours postoperatively	assessed on a four-point scale (1, excellent; 2, good; 3, fair; 4, poor)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026